-+ 0.00%
-+ 0.00%
-+ 0.00%
On November 14, Tianguangshi Biotech announced that its self-developed innovative biological preparation Beijiexin® Dual Indication was successfully included in the new medical insurance catalogue. In February of this year, Beijiexin® was approved to treat neuromyelitis optic disease with positive anti-water channel protein 4 antibodies. In June of the same year, it was also approved for use in adult patients with medium- to high-risk primary membranous nephropathy, making it the first drug approved for pMN in the world.
Share
Listen to the news
On November 14, Tianguangshi Biotech announced that its self-developed innovative biological preparation Beijiexin® Dual Indication was successfully included in the new medical insurance catalogue. In February of this year, Beijiexin® was approved to treat neuromyelitis optic disease with positive anti-water channel protein 4 antibodies. In June of the same year, it was also approved for use in adult patients with medium- to high-risk primary membranous nephropathy, making it the first drug approved for pMN in the world.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending